Investigational Drug Information for KAE609

What is the development status for investigational drug KAE609?

KAE609 is an investigational drug.

There have been 8 clinical trials for KAE609. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1^st 2013.

The most common disease conditions in clinical trials are Malaria, Malaria, Falciparum, and Malaria, Vivax. The leading clinical trial sponsors are Novartis Pharmaceuticals, Wellcome Trust, and Medicine for Malaria Venture.

Summary for KAE609

US Patents	0
International Patents	0
US Patent Applications	112
WIPO Patent Applications	38
Japanese Patent Applications	2
Clinical Trial Progress	Phase 2 (2013-07-01)
Vendors	42

Recent Clinical Trials for KAE609

Title	Sponsor	Phase
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria	Novartis Pharmaceuticals	Phase 2
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria	EDCTP within the PAMAFRICA Grant	Phase 2
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria	European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase 2

See all KAE609 clinical trials

Clinical Trial Summary for KAE609

Top disease conditions for KAE609

Top clinical trial sponsors for KAE609

See all KAE609 clinical trials

US Patents for KAE609

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

KAE609 Cipargamin Development Update and Market Projection

Last updated: September 8, 2026

KAE609, also known as cipargamin and formerly NITD609, is an investigational antimalarial developed by Novartis with Medicines for Malaria Venture support. It is a first-in-class spiroindolone that inhibits the Plasmodium ATP4 ion pump. KAE609 produced rapid parasite clearance in early clinical studies, but it has not progressed to approval or a publicly documented Phase 3 registration program. Its commercial outlook is therefore speculative and materially weaker than that of currently advancing malaria candidates such as ganaplacide.

What is the current development status of KAE609?

KAE609 is a clinical-stage but non-approved antimalarial candidate. Public development activity indicates that it reached Phase 2 testing in uncomplicated malaria, including infections caused by Plasmodium falciparum and Plasmodium vivax. No public FDA, European Medicines Agency, or other major regulatory approval has been reported.

Attribute	KAE609 status
Generic name	Cipargamin
Former development code	NITD609
Drug class	Spiroindolone antimalarial
Molecular target	Plasmodium ATP4
Primary developer	Novartis
Nonprofit collaborator	Medicines for Malaria Venture
Main indication studied	Uncomplicated malaria
Clinical stage reached	Phase 2
FDA approval	None identified
Orange Book listing	None
Commercial launch	None
Public Phase 3 registration program	Not identified
Current development assessment	Inactive, paused, or commercially deprioritized based on public disclosures

KAE609 showed rapid parasite clearance in a randomized Phase 2 trial. Its mechanism is differentiated from artemisinin and partner drugs used in current artemisinin-based combination therapies. The candidate was especially relevant because ATP4 inhibition can kill malaria parasites quickly and may retain activity against parasites resistant to established drug classes (Rottmann et al., 2010; White et al., 2014).

How does cipargamin work against malaria?

Cipargamin inhibits PfATP4, a plasma-membrane cation pump required for parasite ion regulation. ATP4 disruption causes sodium accumulation, osmotic stress, and rapid parasite death.

The mechanism has three commercial implications:

1. It is biologically differentiated from artemisinin, lumefantrine, mefloquine, and other established antimalarials.
2. It may retain activity against parasites resistant to commonly used therapies.
3. It creates a need for combination development because single-agent use would increase resistance risk.

The most likely development path would have been a fixed-dose or co-packaged combination with an unrelated antimalarial. A cipargamin monotherapy launch would have been inconsistent with current malaria-resistance management practices.

What clinical results has KAE609 generated?

The strongest public clinical evidence comes from Phase 2 work in patients with uncomplicated falciparum or vivax malaria. The studies showed rapid parasite clearance and clinical activity after short-course dosing. Cipargamin was assessed in multiple dose regimens rather than as a fully established commercial product.

Reported development issues included dose selection, tolerability, and the need to establish a robust combination partner. Early-stage antimalarial programs can also face electrocardiographic, hepatic, renal, or formulation-related liabilities that affect dose flexibility and pediatric development. Public sources do not establish that one specific safety finding caused discontinuation.

The main clinical strengths are:

• Rapid reduction in parasite burden.
• Activity against falciparum malaria.
• A novel molecular target.
• Potential utility against drug-resistant parasites.
• Suitability for development as part of a new combination regimen.

The main weaknesses are:

• No publicly established Phase 3 efficacy package.
• No approved formulation or commercial dosing schedule.
• No demonstrated pediatric or pregnancy label.
• No confirmed combination regimen.
• No regulatory filing.

When could KAE609 lose exclusivity?

KAE609 has no FDA-approved product exclusivity period because it has not been approved. It also has no Orange Book patent listing or approved-label method-of-use protection.

The compound originated from research involving the Novartis Institute for Tropical Diseases and related malaria research organizations. Patent rights likely cover compound chemistry, salts, formulations, treatment methods, and potentially combinations. Public sources do not establish a single controlling patent expiry date for the entire KAE609 estate.

A practical exclusivity assessment is:

Protection category	Public status
FDA new chemical entity exclusivity	Not available because KAE609 is not approved
Orphan-drug exclusivity	Not identified
Pediatric exclusivity	Not identified
Orange Book patents	None
Compound patents	Likely filed, but controlling expiry is not established from public clinical sources
Combination patents	Possible, with value dependent on the selected partner drug
Formulation patents	Possible, particularly for oral solid dosage forms
Method-of-use patents	Possible for malaria treatment and resistant infections
Regulatory data exclusivity	None currently available

If a key compound patent was filed around the original discovery period, basic patent-term logic could place some protection in the late 2020s or early 2030s, depending on priority dates, patent-term adjustments, continuations, national-phase filings, and terminal disclaimers. That estimate is not a substitute for a jurisdiction-by-jurisdiction patent-family review.

What is the FDA and Orange Book status of KAE609?

KAE609 has no FDA approval, no approved New Drug Application, and no Orange Book listing identified in public FDA records. As a result:

• There is no FDA-recognized reference listed drug.
• No Abbreviated New Drug Application can currently be filed against KAE609 as an approved reference product.
• No Paragraph IV litigation is associated with an approved KAE609 product.
• No FDA exclusivity clock has started.
• Generic entry cannot occur through the conventional ANDA pathway unless cipargamin is first approved.

A future sponsor would probably need to pursue a full NDA or an applicable international regulatory pathway. Any combination product would require additional clinical and chemistry, manufacturing, and controls work.

Are there Paragraph IV challenges or patent lawsuits involving KAE609?

No publicly established Paragraph IV challenge, Hatch-Waxman litigation, or settlement agreement involving an approved KAE609 product has been identified.

The absence of litigation reflects the candidate's development status rather than a confirmed absence of patent rights. Patent litigation normally becomes more likely after:

• Regulatory submission;
• Orange Book listing;
• Commercial launch;
• A generic or competing applicant's Paragraph IV certification;
• A dispute over compound, formulation, or combination patents.

There is also no public evidence of a KAE609-related launch settlement, authorized-generic agreement, or license settlement involving a generic manufacturer.

What companies are developing competing antimalarial drugs?

KAE609 competes with established artemisinin-based therapies and with newer candidates targeting resistance, simplified dosing, or transmission reduction.

Company or organization	Candidate or product	Development relevance
Novartis / MMV	Ganaplacide, formerly KAF156	More visible Novartis-linked next-generation malaria program
Medicines for Malaria Venture partners	Multiple new antimalarial combinations	Nonprofit-supported pipeline addressing resistance and access
Shin Poong Pharmaceutical	Mefloquine-artesunate and related products	Established combination competition
IPCA Laboratories and other manufacturers	Generic ACT products	Price competition in endemic markets
GSK and partners	Tafenoquine	Relapse prevention for P. vivax, not a direct replacement for KAE609
Sanofi and partners	Artesunate-amodiaquine and other malaria products	Existing treatment competition
Bharat Biotech	RTS,S and other malaria-related products	Vaccine competition at the disease-control level, not direct drug substitution

Ganaplacide is the most relevant comparison within the Novartis-associated pipeline. It has a different mechanism and has been positioned for combination development. KAE609 would need a differentiated combination, strong pediatric data, and a procurement-friendly price to regain strategic relevance.

How does KAE609 compare with ganaplacide?

Factor	KAE609 cipargamin	Ganaplacide
Mechanism	ATP4 inhibition	Different novel antimalarial target
Clinical maturity	Phase 2 evidence	More visible later-stage development activity
Monotherapy role	Unlikely for commercial use	Combination-focused
Resistance rationale	High mechanistic differentiation	High mechanistic differentiation
Public regulatory status	Not approved	Not approved
Development momentum	Limited public evidence	Stronger public pipeline visibility
Commercial risk	High	High, but lower relative development risk
Key barrier	Re-activation and combination strategy	Phase 3 execution and registration

A revived KAE609 program would have to overcome the fact that alternative next-generation antimalarials have moved further into development. The opportunity cost of restarting cipargamin trials is therefore significant.

What market opportunity could KAE609 address?

The global malaria burden remains large. The World Health Organization estimated approximately 263 million malaria cases and 597,000 malaria deaths in 2023, with the highest burden in sub-Saharan Africa (World Health Organization, 2024).

The commercial market is structurally different from the market for high-income-country specialty drugs:

• National malaria programs and international procurement agencies are major buyers.
• Pricing is constrained by public-health budgets.
• Volume is high, but unit prices are comparatively low.
• Pediatric formulations are critical.
• Efficacy against resistant parasites affects procurement preference.
• Manufacturing scale and supply reliability can be as important as patent protection.

A reasonable market framework for KAE609 is scenario-based rather than point-estimate forecasting.

Scenario	Assumptions	Potential annual sales
No restart	Program remains inactive	$0
Limited regional launch	Approval in selected endemic countries; niche resistant-malaria use	$25 million-$100 million
Successful public-health launch	Combination approval, African pediatric adoption, broad procurement access	$100 million-$300 million
High-end global adoption	Strong efficacy, low-cost supply, multiple-country tenders, resistance-driven uptake	$300 million-$600 million

These figures are analyst scenarios, not company guidance. A high-end outcome would require a partner drug, Phase 3 success, WHO policy support, prequalification, procurement contracts, and a scalable low-cost manufacturing process.

The probability-weighted value is substantially lower than the high-end sales scenario because KAE609 has not demonstrated a public path to registration. If the current inactive status persists, the product's near-term commercial value is primarily optionality in intellectual property and archived clinical data rather than product revenue.

What manufacturing and formulation barriers affect KAE609?

KAE609 would require a formulation suitable for malaria-endemic populations, including children and patients with limited access to healthcare. Key development requirements would include:

• A stable oral tablet or dispersible pediatric formulation.
• Low manufacturing cost.
• Long shelf life under hot and humid conditions.
• Compatibility with a fixed-dose combination.
• Food-effect and pharmacokinetic characterization.
• Reliable active pharmaceutical ingredient supply.
• Packaging suitable for public-health distribution.

A formulation patent could be commercially important if the active compound patent is close to expiry. Combination patents may also extend practical market protection, but their value would depend on whether the combination is clinically superior and accepted by malaria treatment guidelines.

Is KAE609 a strong patent asset?

KAE609 has potentially valuable technical IP because it is associated with a novel chemical class and a new biological target. Patent strength is not equivalent to commercial strength, however.

The asset's patent position is likely strongest for:

• The original spiroindolone compound class.
• Specific cipargamin compositions.
• Salts and crystalline forms.
• Pharmaceutical formulations.
• Methods of treating malaria.
• Combinations with unrelated antimalarials.

Its effective commercial protection is weaker if:

• Core compound patents are approaching expiry.
• No approved product exists.
• No combination has reached registration.
• Patent ownership or licensing rights are fragmented.
• Manufacturing can be replicated after patent expiry.
• Procurement agencies prioritize low price over brand differentiation.

A formal freedom-to-operate conclusion requires claim-level review of national patent families, legal status, ownership transfers, and term adjustments. Public clinical sources do not establish those details.

What licensing and partnership activity has involved KAE609?

KAE609 was developed within the Novartis malaria research ecosystem with collaboration from Medicines for Malaria Venture and related research institutions. Publicly documented information does not show a commercial out-licensing transaction, regional launch license, generic settlement, or co-commercialization agreement for cipargamin.

A future revival would likely require one of three structures:

1. Novartis-led reactivation with a malaria-focused development partner.
2. Out-licensing to a company with endemic-market manufacturing and procurement expertise.
3. Combination development under a nonprofit or public-private partnership.

The third structure is the most consistent with malaria economics because clinical development, registration, and supply commitments may be difficult to support through commercial pricing alone.

What are the likely generic launch scenarios for KAE609?

There is no near-term generic launch scenario because KAE609 is not approved. The realistic pathways are:

• No launch if the program remains inactive.
• A new sponsor revives development and files an NDA.
• A partner develops cipargamin as part of a fixed-dose combination.
• A manufacturer pursues development after key patents expire, subject to regulatory requirements.

Even after patent expiry, generic entry would not be automatic. A generic or follow-on manufacturer would need an approved reference product, sufficient clinical and bioequivalence data, an acceptable formulation, and regulatory authorization in each target jurisdiction.

Key Takeaways

• KAE609, or cipargamin, is an investigational ATP4-inhibiting antimalarial.
• It generated encouraging Phase 2 parasite-clearance data but has no public approval or established Phase 3 registration path.
• The candidate has no FDA exclusivity, Orange Book listing, or Paragraph IV litigation.
• Its commercial opportunity depends on combination development, pediatric formulation, resistance advantages, and public procurement.
• A plausible successful-launch range is $100 million-$300 million annually, but the no-restart scenario remains the most defensible near-term base case.
• Ganaplacide has greater visible development momentum within the Novartis-linked malaria portfolio.
• KAE609's patent value may be meaningful, but no single controlling expiry date is established from public clinical sources.

FAQs

Is KAE609 the same drug as cipargamin?

Yes. KAE609 is the development code for cipargamin, which was previously known as NITD609.

Is cipargamin approved for malaria?

No. Cipargamin has not received FDA, EMA, or other major-market approval identified in public regulatory sources.

Can cipargamin treat artemisinin-resistant malaria?

Its novel ATP4 mechanism provides a rationale for activity against parasites resistant to artemisinin-based therapies, but clinical use against resistant malaria would require regulatory evidence and an approved treatment regimen.

Does KAE609 have a pediatric formulation?

A commercially approved pediatric formulation has not been established. Pediatric development would be necessary for broad African and public-sector adoption.

What would increase the value of KAE609?

A successful restart into combination Phase 3 development, strong efficacy against resistant parasites, a low-cost pediatric formulation, WHO prequalification, and a licensing deal with an endemic-market manufacturer would materially improve its value.

References

1. Medicines for Malaria Venture. (n.d.). Malaria medicines pipeline. https://www.mmv.org/research-development

2. Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., Cohen, S. B., Späth, G. F., Gulab, S. A., Goraj, V., Goh, A., Suwanarusk, R., Taylor, C. J., Fidock, D. A., & Wirth, D. F. (2010). Spiroindolones, a potent and novel class of antimalarial agents. Science, 329(5996), 1175-1180. https://doi.org/10.1126/science.1193225

3. White, N. J., Pukrittayakamee, S., Phyo, A. P., Rueangweerayut, R., Nosten, F., Jittamala, P., Jeeyapant, A., Jain, J. P., Lefèvre, G., Li, R., Magnusson, B., Tärning, J., & Chandra, R. (2014). Spiroindolone KAE609 for falciparum and vivax malaria. The New England Journal of Medicine, 371(5), 403-410. https://doi.org/10.1056/NEJMoa1315860

4. World Health Organization. (2024). World malaria report 2024. World Health Organization. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024